Treatment of inflammatory disorders
A method of treating an inflammatory disease or an autoimmune disease in a subject, comprises the administration of mefloquine.
1 . Use of (+)-erythro-mefloquine, substantially free of (−)-erythro-mefloquine, for the manufacture of a medicament for the treatment of an inflammatory disease selected from the group consisting of rheumatoid arthritis, osteoarthritis, psoriatic arthritis, psoriasis, Crohn's disease, systemic lupus erythematosus, ulcerative colitis, COPD and asthma.
2 . The use, according to claim 1 , wherein the inflammatory disease is rheumatoid arthritis.
3 . The use, according to claim 1 , wherein the inflammatory disease is osteoarthritis.
4 . A method for treating an inflammatory disease selected from the group consisting of rheumatoid arthritis, osteoarthritis, psoriatic arthritis, psoriasis, Crohn's disease, systemic lupus erythematosus, ulcerative colitis, COPD and asthma, wherein said method comprises administering, to a patient in need of such treatment, (+)-erythro-mefloquine, substantially free of (−)-erythro-mefloquine.
5 . The method, according to claim 4 , wherein the inflammatory disease is rheumatoid arthritis.
6 . The method, according to claim 4 , wherein the inflammatory disease is osteoarthritis.
7 . The method, according to claim 4 , further comprising first identifying said patient in need.